1. Introduction

CRISPR clinical application limits refer to the scientific, ethical, legal, constitutional and regulatory restrictions governing the use of CRISPR-based gene-editing technologies in human medical treatment, disease prevention and reproductive applications.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing technology that enables scientists to modify DNA at targeted locations. The CRISPR-Cas9 system uses a guide RNA to direct the Cas9 enzyme to a particular DNA sequence, where the enzyme cuts the DNA and allows genetic modification.

CRISPR has significant clinical potential in treating:

Sickle-cell disease and beta-thalassemia.

Certain inherited retinal disorders.

Genetic immunological disorders.

Cancer through genetically modified immune cells.

Certain inherited metabolic diseases.

Rare genetic and neurological disorders.

However, the ability to modify human DNA does not automatically establish a legal right to use that technology in clinical practice.

Clinical applications are limited by concerns relating to patient safety, unintended genetic alterations, informed consent, long-term monitoring, reproductive consequences, genetic discrimination, environmental risks and the possibility of irreversible changes to future generations.

The central legal principle is that scientific innovation must operate within the boundaries of patient safety, human dignity, informed consent and regulatory accountability.

2. Scientific Limitations of CRISPR Clinical Applications

A. Off-target genetic modifications

Off-target effects occur when CRISPR-Cas9 modifies DNA sequences other than the intended target.

For example, a CRISPR treatment intended to correct a mutation responsible for sickle-cell disease might unintentionally modify another genetic region.

Potential consequences include:

Activation of cancer-associated genes.

Disruption of essential cellular functions.

Unexpected immune responses.

Genetic instability.

Development of abnormal cells.

Legal significance: Pharmaceutical companies and clinical researchers must demonstrate that the treatment has acceptable safety characteristics before administering it to patients.

A clinical trial cannot be justified merely because the intended genetic modification is scientifically promising.

B. On-target unintended consequences

Even when CRISPR modifies the correct DNA location, the resulting genetic alteration may be unpredictable.

Possible consequences include:

Large DNA deletions.

Chromosomal rearrangements.

Unintended insertions.

Loss of important genetic functions.

Abnormal DNA repair.

Therefore, successful targeting does not necessarily mean successful treatment.

C. Mosaicism

Mosaicism occurs when only some cells contain the intended genetic modification, while other cells remain genetically unchanged or carry different modifications.

This creates difficulties in determining:

Whether treatment has corrected the disease.

Whether modified cells will remain stable.

Whether untreated cells will continue causing disease.

Whether unexpected genetic changes will develop.

D. Delivery limitations

CRISPR components must reach the appropriate cells and tissues.

Delivery methods include:

Viral vectors.

Lipid nanoparticles.

Electroporation.

Ex vivo cellular modification.

Each method presents different risks concerning immune reactions, tissue distribution, toxicity and treatment effectiveness.

E. Long-term uncertainty

Some genetic modifications may produce consequences that become apparent only years after treatment.

This creates difficulties concerning:

Lifetime monitoring.

Delayed adverse effects.

Cancer development.

Genetic instability.

Reproductive consequences.

Responsibility for future medical expenses.

Legal principle: Clinical approval should be based on an adequate assessment of both immediate and reasonably foreseeable long-term risks.

3. Legal and Regulatory Limitations of CRISPR

A. Somatic gene editing versus germline gene editing

One of the most important legal distinctions is between somatic and germline genome editing.

Somatic gene editing: This involves modifying cells such as blood, immune or liver cells. The modification is generally not transmitted to offspring.

Germline gene editing: This involves modifying reproductive cells or embryos in a manner capable of transmitting genetic changes to future generations.

The distinction is important because germline modification raises questions concerning the rights of future children, reproductive autonomy, genetic inequality and the absence of consent from future generations.

The International Society for Stem Cell Research (ISSCR) maintains a restrictive approach towards reproductive applications of heritable human genome editing.

PMC+1

B. Restriction on reproductive genome editing

CRISPR should not be used to create genetically modified children without an adequate scientific, ethical and legal framework.

Major concerns include:

Inability to obtain consent from future generations.

Unpredictable genetic consequences.

Potential transmission of harmful mutations.

Creation of genetic inequalities.

Commercialisation of reproductive characteristics.

Possibility of eugenic practices.

The 2018 controversy involving Chinese scientist He Jiankui, who used CRISPR to modify human embryos resulting in the birth of gene-edited children, demonstrated the consequences of inadequate ethical and regulatory oversight.

The incident resulted in criminal proceedings in China and strengthened international demands for responsible human genome-editing governance.

C. Clinical trial approval limitations

CRISPR-based treatments cannot ordinarily be introduced into medical practice simply because laboratory experiments demonstrate effectiveness.

Clinical development generally requires:

Preclinical safety and efficacy studies.

Validated genetic-editing methods.

Assessment of off-target effects.

Manufacturing quality controls.

Institutional ethics approval.

Regulatory authorisation.

Informed patient consent.

Adverse-event reporting.

Appropriate long-term follow-up.

In the United States, the FDA's January 2024 guidance establishes recommendations for human gene-therapy products incorporating genome editing. Its April 2026 draft guidance additionally addresses next-generation sequencing methods for evaluating potential genome-editing risks.

FDA+1

D. Limitations on enhancement applications

CRISPR clinical applications should principally be distinguished from non-therapeutic genetic enhancement.

Examples of enhancement include:

Increasing intelligence.

Altering physical appearance.

Increasing athletic performance.

Modifying height.

Selecting socially preferred characteristics.

Attempting to extend lifespan through unproven genetic interventions.

The distinction between disease treatment and enhancement is legally important because medical necessity, proportionality and acceptable risk may differ substantially.

A treatment for a serious genetic disorder may offer a defensible medical justification. Modifying an otherwise healthy embryo to achieve a preferred physical characteristic raises considerably different ethical and legal concerns.

E. Informed consent limitations

CRISPR treatment may involve complicated and uncertain risks that patients cannot easily understand.

Valid informed consent should explain:

The nature of the genetic modification.

Expected therapeutic benefits.

Known and uncertain risks.

Alternative treatments.

Possibility of treatment failure.

Long-term monitoring requirements.

Privacy risks involving genetic information.

Possibility of additional medical intervention.

Consent must be voluntary and free from coercion.

Special safeguards are necessary where children, persons lacking decision-making capacity or terminally ill patients participate in research.

F. Genetic privacy and discrimination

CRISPR clinical treatment requires the collection and analysis of highly sensitive genetic information.

Such information may reveal:

Inherited disease risks.

Family relationships.

Genetic predispositions.

Carrier status.

Information about biological relatives.

Unauthorised disclosure may create risks of discrimination in employment, insurance and social relationships.

Clinical institutions must therefore maintain appropriate data security, confidentiality, access controls and lawful data-processing practices.

4. CRISPR Clinical Applications in India

India regulates gene-therapy development through a combination of biotechnology, pharmaceutical, clinical-trial, environmental and ethical requirements.

The principal regulatory framework includes:

1. National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019

These guidelines provide the framework for developing, evaluating and conducting clinical trials involving gene-therapy products.

2. New Drugs and Clinical Trials Rules, 2019

These rules govern regulatory permissions for applicable new drugs and clinical trials, including relevant gene-therapy products.

3. Drugs and Cosmetics Act, 1940

This legislation provides the statutory foundation for the regulation of drugs and related clinical research activities.

4. Environment (Protection) Act, 1986

This Act provides the legislative foundation for India's biosafety framework.

5. Rules, 1989

The Rules for the Manufacture, Use, Import, Export and Storage of Hazardous Micro-organisms/Genetically Engineered Organisms or Cells establish regulatory oversight for relevant genetically engineered materials and activities.

6. ICMR Ethical Guidelines

These guidelines establish ethical principles for biomedical and health research involving human participants, including genetic research.

7. Institutional and regulatory oversight

Relevant authorities and institutional bodies include:

CDSCO – Central Drugs Standard Control Organisation.

DCGI – Drugs Controller General of India.

ICMR – Indian Council of Medical Research.

DBT – Department of Biotechnology.

RCGM – Review Committee on Genetic Manipulation.

IBSC – Institutional Biosafety Committee.

Institutional Ethics Committees.

The Indian Government confirmed in a parliamentary response dated 19 March 2026 that CRISPR-based therapies are subject to the 2019 gene-therapy guidelines, applicable biosafety requirements and oversight under the NDCT Rules, 2019.

Press Information Bureau+1

Specific Indian restriction on germline editing

The Indian framework distinguishes laboratory research from reproductive use.

The National Guidelines for Stem Cell Research, 2017, restrict genome modification of human germline stem cells, gametes and embryos to in-vitro research under the applicable institutional and regulatory oversight framework.

Consequently, permission to conduct laboratory research does not amount to permission to use genetically modified embryos for reproduction.

sts.icmr.org.in+1

5. Important Case Laws Relating to CRISPR Clinical Application Limits

There are relatively few reported judicial decisions directly concerning CRISPR-based clinical treatment. Nevertheless, several important judgments establish legal principles that apply to gene editing, experimental medical interventions, informed consent, medical negligence, privacy and reproductive autonomy.

1. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Supreme Court of India

Facts: The patient consented to a diagnostic procedure, but the doctor performed additional surgical procedures without obtaining her specific consent.

Judgment: The Supreme Court held that valid medical consent must be voluntary, given by a competent person and based on adequate information about the treatment.

Relevance to CRISPR:

Patients must understand the nature of genetic modification.

Doctors must disclose substantial risks.

Consent for one medical procedure cannot automatically authorise a different procedure.

Experimental genetic treatment requires meaningful consent.

Legal principle: Patient autonomy restricts the ability of medical professionals to undertake unauthorised interventions.

Indian Kanoon+1

2. Common Cause v. Union of India (2018) 5 SCC 1

Supreme Court of India

Facts: The case concerned passive euthanasia, advance medical directives and the constitutional right to die with dignity.

Judgment: The Supreme Court recognised the importance of dignity, autonomy and individual choice under Article 21 of the Constitution.

Relevance to CRISPR:

The judgment provides constitutional support for:

Patient autonomy in medical decision-making.

Respect for individual dignity.

Voluntary treatment decisions.

Protection against unwanted medical intervention.

It is relevant when considering whether a patient can refuse a proposed gene-editing procedure despite its potential medical benefits.

Patna High Court

3. Jacob Mathew v. State of Punjab (2005) 6 SCC 1

Supreme Court of India

Facts: The case concerned allegations of criminal negligence against medical professionals following a patient's death.

Judgment: The Supreme Court explained the standards applicable to criminal medical negligence and emphasised that criminal liability requires a sufficiently high degree of negligence.

Relevance to CRISPR:

A doctor or researcher involved in CRISPR treatment may face legal consequences where serious negligence is established.

Examples include:

Failure to follow established safety protocols.

Negligent administration of gene-editing treatment.

Failure to monitor serious adverse reactions.

Deliberate disregard of regulatory requirements.

However, an unsuccessful treatment or an adverse outcome does not automatically establish criminal negligence.

Indian Kanoon

4. He Jiankui Human Embryo Gene-Editing Criminal Case (China, 2019)

Directly related to CRISPR

Facts: Chinese scientist He Jiankui conducted experiments involving CRISPR modification of human embryos, resulting in the birth of genetically edited children.

The experiments involved modification of the CCR5 gene, with the stated objective of attempting to confer resistance to HIV.

Judgment: In December 2019, a court in Shenzhen sentenced He Jiankui to three years' imprisonment and imposed a fine of three million yuan. Two collaborators also received sentences.

The court found that the defendants had violated medical and research regulations, lacked the necessary qualifications and conducted the experiments without establishing safety and effectiveness.

Supreme People's Court of China

Relevance to CRISPR:

This is an important direct legal precedent demonstrating that:

Human embryo editing cannot bypass regulatory approval.

Scientific innovation does not excuse violations of medical regulations.

Reproductive genome editing raises serious ethical and legal concerns.

Researchers may face criminal liability for unlawful experimentation.

5. Justice K.S. Puttaswamy v. Union of India (2017) 10 SCC 1

Supreme Court of India

Facts: The case concerned the constitutional recognition of privacy as a fundamental right.

Judgment: The Supreme Court unanimously recognised privacy as a fundamental right under Article 21 and other freedoms guaranteed by Part III of the Constitution.

Relevance to CRISPR:

Genetic information is particularly sensitive because it may reveal information about an individual's biological identity and family.

The judgment is relevant to:

Genetic privacy.

Confidentiality of genomic records.

Control over personal biological information.

Protection against unauthorised genetic surveillance.

Privacy in clinical genetic research.

CRISPR researchers must therefore consider privacy and data-protection obligations when collecting, processing and storing genetic information.

6. Association for Molecular Pathology v. Myriad Genetics, Inc. (2013), 569 U.S. 576

United States Supreme Court

Facts: The dispute concerned whether naturally occurring human DNA sequences could be patented merely because they had been isolated.

Judgment: The US Supreme Court held that naturally occurring DNA is not patent-eligible merely because it has been isolated. Synthetically created cDNA may be patent-eligible, subject to applicable patent requirements.

Relevance to CRISPR:

This case is important for understanding:

Patent protection for biotechnology inventions.

Commercial ownership of genetic technologies.

Access to genetic diagnostic and therapeutic innovations.

The distinction between naturally occurring biological material and human-created inventions.

It does not directly regulate clinical CRISPR treatment, but it establishes important boundaries for biotechnology intellectual property.

6. Approved CRISPR Treatment and Its Legal Significance

An important development is the approval of Casgevy (exagamglogene autotemcel).

Breakthrough Gene Therapy for Sickle Cell and Thalassemia Unveiled in Abu Dhabi

Casgevy – CRISPR-Cas9 therapy

FDA approved

Uses CRISPR-Cas9 to modify a patient's blood stem cells.

Targets the BCL11A erythroid-specific enhancer.

Increases fetal haemoglobin production.

Used for sickle-cell disease and transfusion-dependent beta-thalassemia.

The FDA initially approved Casgevy for sickle-cell disease in December 2023 and for transfusion-dependent beta-thalassemia in January 2024. Its regulatory indications were subsequently expanded.

FDA+1

This treatment demonstrates that CRISPR is not prohibited as a general category of medical technology.

However, approval of one particular treatment does not automatically authorise every CRISPR application.

The following distinctions remain important:

7. Liability for Improper CRISPR Clinical Applications

Different forms of legal liability may arise from unsafe or unauthorised CRISPR applications.

A. Liability of researchers

Researchers may be held accountable for:

Falsifying experimental results.

Concealing genetic abnormalities.

Misrepresenting clinical outcomes.

Conducting unauthorised embryo experiments.

Failing to report serious adverse events.

B. Liability of pharmaceutical companies

Manufacturers may face liability where they:

Release defective gene-editing products.

Provide misleading safety information.

Fail to maintain manufacturing standards.

Conceal known product risks.

Fail to comply with applicable pharmacovigilance obligations.

C. Liability of hospitals and medical practitioners

Hospitals may face liability for:

Administering unapproved treatments.

Employing inadequately qualified personnel.

Obtaining defective consent.

Failing to conduct appropriate clinical assessments.

Neglecting post-treatment monitoring.

8. Constitutional and Human Rights Dimensions

CRISPR clinical applications raise important constitutional questions.

Article 14 – Right to Equality

Genetic treatment should not become a mechanism for discrimination between individuals based on genetic characteristics or economic circumstances.

Article 19 – Freedom and Personal Liberty

The broader constitutional protection of individual freedom is relevant to reproductive choices, medical decision-making and scientific freedom, subject to applicable restrictions.

Article 21 – Right to Life and Personal Liberty

Article 21 is particularly important because it encompasses:

Human dignity.

Bodily integrity.

Privacy.

Patient autonomy.

Access to appropriate healthcare.

Protection against unsafe medical experimentation.

International human rights principles

The Universal Declaration on the Human Genome and Human Rights, 1997, emphasises human dignity and the need to protect individuals against genetic discrimination.

The WHO's 2021 recommendations also emphasise international cooperation, transparency, public engagement and effective oversight of human genome editing.

World Health Organization+1

9. Major Challenges in Regulating CRISPR Clinical Applications

The most significant regulatory challenges include:

1. Scientific uncertainty: Long-term genetic consequences cannot always be predicted.

2. Cross-border medical tourism: Patients may travel to jurisdictions offering inadequately regulated treatments.

3. Regulatory fragmentation: Different countries adopt different approaches to somatic and germline editing.

4. Commercial exploitation: Companies may advertise experimental treatments as established cures.

5. Genetic inequality: Expensive therapies may remain inaccessible to economically disadvantaged patients.

6. Intergenerational responsibility: Germline modifications may affect people who cannot consent.

7. Long-term monitoring: Responsibility for follow-up may become unclear when researchers, manufacturers and hospitals change ownership or cease operations.

8. Evidence standards: Regulators must determine what level of preclinical and clinical evidence is sufficient for approval.

9. Genetic data security: Genomic information requires appropriate privacy and security safeguards.

10. Regulatory accountability: Authorities must be able to investigate unauthorised research and enforce applicable standards.

10. Recommendations for Improving CRISPR Clinical Regulation

A responsible legal framework should incorporate the following safeguards:

Mandatory preclinical safety assessment.

Comprehensive off-target analysis.

Independent scientific and ethical review.

Clear separation between somatic and germline applications.

Strict control of reproductive genome editing.

Transparent clinical-trial registration.

Specific informed-consent procedures.

Long-term patient monitoring.

Mandatory adverse-event reporting.

Genetic privacy and confidentiality safeguards.

Independent inspection of gene-editing facilities.

Effective civil and criminal remedies for regulatory violations.

Equitable access to approved genetic therapies.

The WHO governance framework and FDA genome-editing guidance provide useful international reference points for developing these safeguards.

World Health Organization+2

11. Conclusion

CRISPR represents a major development in modern medicine because it provides opportunities to treat genetic diseases at their biological source. However, its clinical application must remain subject to scientific validation, regulatory supervision, ethical restrictions and constitutional protections.

The law must distinguish between responsible therapeutic intervention and potentially dangerous genetic experimentation.

The cases of Samira Kohli, Jacob Mathew, Common Cause and Puttaswamy establish important principles of patient consent, medical accountability, dignity and privacy. The He Jiankui criminal proceedings provide a direct example of the consequences of unlawful human embryo gene editing.

The fundamental legal position is that CRISPR technology may be used for legitimate medical purposes within an appropriate regulatory framework, but scientific capability alone cannot establish clinical legality.

12. Important Legal References for Further Study

Important academic qualification: The Indian Supreme Court cases discussed above are analogous legal precedents, not judgments directly deciding the legality of CRISPR treatment. The He Jiankui proceedings are a direct CRISPR-related criminal case, while Myriad Genetics concerns biotechnology patentability rather than clinical safety.

For legal research, this distinction is essential because it prevents general medical-law principles from being incorrectly presented as CRISPR-specific judicial rulings.